A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Daptomycin (DAPZURA RT)

Daptomycin for injection is a lipopeptide antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of ag....

First FDA approval2018-01-15
Generic availableYes · 16 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$188.0M in CY2024 Part D spend233K claims · 56K beneficiaries · 329 plans surveyed

Lowest NADAC
$13.42/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$15.99
Across all dosage forms in distribution.
Highest NADAC
$20.77
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Daptomycin used for?

Daptomycin for injection is a lipopeptide antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of ag....

Is there a generic for Daptomycin?

Yes. 21 ANDAs filed at FDA, 16 generic manufacturers currently shipping.

How much does my plan pay for Daptomycin?

Across 329 Part D plans, Daptomycin averages $15.99/unit (NADAC). Lowest available: $13.42/unit. Highest in distribution: $20.77/unit.

Is Daptomycin on the FDA shortage list?

No. Daptomycin is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Lipopeptide Antibacterial1 alternative in D1
01
Daptomycin In Sodium
Lipopeptide Antibacterial
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.